19387108|t|Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis.
19387108|a|Obesity, type 2 diabetes mellitus (T2DM), and non-alcoholic steatohepatitis (NASH) can be complicated by cognitive impairment and neurodegeneration. Experimentally, high fat diet (HFD)-induced obesity with T2DM causes mild neurodegeneration with brain insulin resistance. Since ceramides are neurotoxic, cause insulin resistance, and are increased in T2DM, we investigated the potential role of ceramides as mediators of neurodegeneration in the HFD obesity/T2DM model. We pair-fed C57BL/6 mice with a HFD or control diet for 4-20 weeks and examined pro-ceramide gene expression in liver and brain and neurodegeneration in the temporal lobe. HFD feeding gradually increased body weight, but after 16 weeks, liver weight surged (P<0.001) due to lipid (triglyceride) accumulation (P<0.001), and brain weight declined (P<0.0001-Trend analysis). HFD feeding increased ceramide synthase, serine palmitoyl transferase, and sphingomyelinase expression in liver (P<0.05-P<0.001), but not brain. In HFD fed mice, temporal lobe levels of ubiquitin (P<0.001) and 4-hydroxynonenal (P<0.05 or P<0.01) increased, and tau, beta-actin, and choline acetyltransferase levels decreased (P<0.05-P<0.001) with development of NASH. In obesity, T2DM, or NASH, neurodegeneration with brain insulin resistance may be mediated by excess hepatic production of neurotoxic ceramides that readily cross the blood-brain barrier.
19387108	8	16	ceramide	Chemical	MESH:D002518
19387108	35	53	insulin resistance	Disease	MESH:D007333
19387108	58	75	neurodegeneration	Disease	MESH:D019636
19387108	79	94	type 2 diabetes	Disease	MESH:D003924
19387108	99	128	non-alcoholic steatohepatitis	Disease	MESH:D005235
19387108	130	137	Obesity	Disease	MESH:D009765
19387108	139	163	type 2 diabetes mellitus	Disease	MESH:D003924
19387108	165	169	T2DM	Disease	MESH:D003924
19387108	176	205	non-alcoholic steatohepatitis	Disease	MESH:D005235
19387108	207	211	NASH	Disease	MESH:D005235
19387108	235	255	cognitive impairment	Disease	MESH:D003072
19387108	260	277	neurodegeneration	Disease	MESH:D019636
19387108	323	330	obesity	Disease	MESH:D009765
19387108	336	340	T2DM	Disease	MESH:D003924
19387108	353	370	neurodegeneration	Disease	MESH:D019636
19387108	382	400	insulin resistance	Disease	MESH:D007333
19387108	408	417	ceramides	Chemical	MESH:D002518
19387108	422	432	neurotoxic	Disease	MESH:D020258
19387108	440	458	insulin resistance	Disease	MESH:D007333
19387108	481	485	T2DM	Disease	MESH:D003924
19387108	525	534	ceramides	Chemical	MESH:D002518
19387108	551	568	neurodegeneration	Disease	MESH:D019636
19387108	580	587	obesity	Disease	MESH:D009765
19387108	588	592	T2DM	Disease	MESH:D003924
19387108	612	619	C57BL/6	CellLine	CVCL:C0MU
19387108	620	624	mice	Species	10090
19387108	684	692	ceramide	Chemical	MESH:D002518
19387108	732	749	neurodegeneration	Disease	MESH:D019636
19387108	874	879	lipid	Chemical	MESH:D008055
19387108	881	893	triglyceride	Chemical	MESH:D014280
19387108	1128	1132	mice	Species	10090
19387108	1182	1198	4-hydroxynonenal	Chemical	MESH:C027576
19387108	1238	1248	beta-actin	Gene	11461
19387108	1254	1279	choline acetyltransferase	Gene	12647
19387108	1334	1338	NASH	Disease	MESH:D005235
19387108	1343	1350	obesity	Disease	MESH:D009765
19387108	1352	1356	T2DM	Disease	MESH:D003924
19387108	1361	1365	NASH	Disease	MESH:D005235
19387108	1367	1384	neurodegeneration	Disease	MESH:D019636
19387108	1396	1414	insulin resistance	Disease	MESH:D007333
19387108	1463	1473	neurotoxic	Disease	MESH:D020258
19387108	1474	1483	ceramides	Chemical	MESH:D002518
19387108	Positive_Correlation	MESH:D002518	MESH:D020258
19387108	Positive_Correlation	MESH:D002518	MESH:D003924
19387108	Positive_Correlation	MESH:C027576	MESH:D005235
19387108	Positive_Correlation	MESH:D002518	MESH:D019636
19387108	Association	MESH:D005235	11461
19387108	Association	MESH:D002518	MESH:D005235
19387108	Positive_Correlation	MESH:D002518	MESH:D007333
19387108	Association	MESH:D005235	12647

